

EDUCATION

INTERNATIONAL EVENTS

In 2019, EUREOS held its second EoE symposium during UEGW in Barcelona.

Main topics were:

- Inclusion criteria: PPI-REE, plain EoE or refractory EoE?
(Alfredo Lucendo, Tomelloso, Spain)
- Core outcome set in EoE (Ekaterina Safroneeva, Bern, Switzerland)
- Relevant read-outs in maintenance treatment studies in EoE
(Luc Biedermann, Zurich, Switzerland)

EXPERT RECOMMENDATIONS

EoE CORE OUTCOME SET PROJECT (COREOS)

Core outcome sets are an agreed, standardised list of outcomes that should be measured and reported in all trials in specific clinical areas. We aim to develop a core outcome set for EoE, thus coming up with recommendations for endpoints in clinical trials and other EoE studies.

Under the patronage of EUREOS, the COREOS project was launched in 2018 in collaboration with CEGIR, EGID Committee of AAAAI, and Robarts Clinical Trials (recently renamed to Alimentiv).

An expert meeting was held in spring 2019, publication of the COREOS final report is expected for winter 2020/2021.

ACKNOWLEDGEMENTS

We thank our corporate members for their financial support.

PATIENT ADVOCACY

ROLE MODEL: EOS NETWORK, UK

EOS Network stands out as an essential charity based in the UK with a unique global role in the fight against Eosinophilic Diseases. Aim of the EOS Network is to support patients, families and caregivers through its charity activities. For more information, please visit www.eosnetwork.org.

EUREOS has established a very close collaboration with EOS Network, thus including EOS Networks' trustee and chair Amanda Cordell as speaker in our EoE Symposium in 2020.

EUREOS ANNUAL REPORT 2019/20

Arjan Bredenoord, President

Alfredo Lucendo, President Elect

ADDRESS

Arjan Bredenoord
Gastroenterologist AMC Amsterdam
Committee's Office

www.eureos.online
info.eureos@gmail.com
www.centerview.ch

ABOUT EUREOS

EUREOS is the meeting point for clinicians and researchers to share knowledge on EoE. The objective of the organization is to establish and maintain a network and a communication platform for physicians and researchers with a specific interest in eosinophilic esophagitis (EoE) and eosinophilic gastro-enteritis and/or eosinophilic colitis in Europe.

STEERING COMMITTEE

The EUREOS steering committee 2019-2020 consists of

- Arjan Bredenoord (President 2017-2021)
- Alfredo Lucendo (Vice-President 2017-2021)
- Luc Biedermann (Treasurer)
- Stephan Miehlke
- Matteo Ghisa (Communication Officer)
- Christoph Schlag (Education Officer)
- Salvatore Oliva (Pediatric Officer)
- Helen Larsson (Content Manager)
- Ulrike von Armin (Guideline Officer)

MEMBERS



EUREOS is currently supported by 127 members from 16 different European countries. We invite all physicians and scientist interested in EoE or wanting to support our work to become a member.

Members can participate in the annual general assembly and play an active role in deciding about future activities of EUREOS. Membership is free for physicians and scientists.

Furthermore, our members have access to the password-protected member area containing several valuable information and a slide library.

COMMUNICATION PLATFORM

In the past, EUREOS had built two web platforms to spread knowledge on EoE, as a reference resource to provide patients, caregivers and physicians with information regarding the disease.

In 2019/20 we have now harmonized our communication platforms and unified eureos.online and EoE LINK into one site, targeted at to physicians, healthcare professionals and researchers within the "Professionals" section, and patients and caregivers in the "Patient" section. Please visit us on www.eureos.online

PAST & CURRENT ACTIVITIES

RESEARCH

EoE CONNECT

European Registry of Clinical, Environmental and Genetic Determinants in Eosinophilic Esophagitis

In 2016 EUREOS created an advanced multilingual EoE database with the aim to improve knowledge on epidemiology, its evolving trends, and on its burden to the health systems across Europe. The registry serves as a base for implementation of further prospective collaborative studies and is open to patients from all Europe. To date about 750 patients have been registered in EoE CONNECT.

Detailed research objectives are the following:

- To describe the socio-demographical and clinical characteristics as well as personal antecedents of EoE patients.
- To examine the relationship between time of disease onset, length of diagnostic delay, and disease phenotypes.
- To determine the influence of environmental and genetic factors on the time of onset, natural history and course of EoE.
- To analyse the use, effectiveness, and safety of the different therapeutic interventions in EoE, both in short and long term, using the standardized set of outcomes.
- To examine the burden of disease costs associated with EoE in adults.

EoE CONNECT is run under the patronage of EUREOS with a scientific committee of ten international EoE experts. Contributors, that have added more than 30 patients in the EoE registry, can submit a study request to the scientific committee using the data in the EoE registry.

The following studies have been published using the EoE CONNECT database:

- Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice (Clin Gastroenterol Hepatol. 2020 Jan 25;S1542-3565(20)30103-8)
- Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry (Pharmacol Ther. 2020 Sep;52(5):798-807. doi: 10.1111/apt.15957. Epub 2020 Jul 17.)

Industry-driven clinical trials

EUREOS has been approached by several pharmaceutical companies to collaborate in their clinical trials.

If you are interested in participation as a study centre and you have the facilities, please contact us.